View Open Trials
Bladder
-
20172 - PH 2 Enfortumab in Urothelial Pts
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
-
18095 - NeoAdj Chemo +/- Nivo/IDO1inh MIBC
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)
Breast
-
20396 - Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
-
20210 - Registry study with Breast Cancer Index
Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
-
17079 - FLEX Registry: Evaluate New Gene Express
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Lung (Non Small Cell)
-
20270 - Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
-
20412 - Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
-
20137 - PH3 Atez Tira Dura Sg 3 NSCLC
GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)
-
BIODESIX
Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)
Lymphomas
-
21356 - Ph2 Sub Mosunetuzumab B-cell malig
AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Melanoma
-
20430 - Ph2 Selinexor + Pembro Newly Dx Melanoma - ON ENROLLMENT HOLD
A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN RECURRENT ADVANCED MELANOMA (XPORT-MEL-033)
Prostate
-
20248 - PH3 Nirap Abira HRR mCSPC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Renal
-
GU-102 Ph I/II Nivo + axitinib RCC
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Solid Tumors
-
20283 - Ph2 Bren Vedo + Pembro ST prior PD-1
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
-
19151 - Ph1/2 MRTX849 Solids KRAS G12C
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
-
19043 - Ph2 IMMU-132 met Solid Tumors
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)